USA flag logo/image

An Official Website of the United States Government

Novel human anti-uPAR antibodies for the treatment of pancreatic cancer

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
93514
Program Year/Program:
2009 / SBIR
Agency Tracking Number:
CA137884
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
AVANTGEN, INC.
AVANTGEN, INC. 10151 Pacific Mesa Blvd. SAN DIEGO, CA 92129-4571
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2009
Title: Novel human anti-uPAR antibodies for the treatment of pancreatic cancer
Agency: HHS
Contract: 1R43CA137884-01A1
Award Amount: $158,025.00
 

Abstract:

DESCRIPTION (provided by applicant): Cancers that are typically diagnosed as late-stage, metastatic disease, such as pancreatic cancer, have remained refractory to standard radiation, surgical and chemotherapy. With all the advance of newer more targeted a gents, pancreatic cancer 5-year mortality rates remain a dismal 93% underscoring the urgent need to identify targets that can be used to block the metastatic process. The uPA system has shown promise as one such target. However, a major limitation of pre-c linical studies is that metastasis involves both tumor and surrounding stromal tissue-derived uPA and its receptor, uPAR. We plan to use a proprietary yeast display library and competitive screening method to try and identify antibodies that can block both human and mouse uPAR and uPA and then test each antibody in an orthotopic model of pancreatic cancer, both as individual monotherapies and in combination with gemcitabine, to evaluate their relative efficacy as inhibitors of the metastatic process. PUBLIC HEALTH RELEVANCE: Despite the progress that has been made over the past 10 to 20 years in identifying cancer treatments that are less toxic than standard chemotherapy, there has been little success in improving the outcome of patients who are diagnosed wi th advanced, late-stage disease that has spread throughout the body (metastatic disease). The goals of this application are to generate very potent antibodies directed against two components of a system, the so-called urokinase system, that appears to play a major role in the invasive processes underlying cancer spread and metastasis and test them in a model of pancreatic cancer. If they prove successful in these pre-clinical models, these antibodies can be directly developed into novel therapeutic agents f or treatment of human pancreatic cancer.

Principal Investigator:

Xiaomin Fan
8585389866
XFAN@AVANTGEN.COM

Business Contact:

Catherine M. Woods
cmwoods@avantgen.com
Small Business Information at Submission:

AVANTGEN, INC.
AVANTGEN, INC. 12240 KATYDID CIR SAN DIEGO, CA 92129

EIN/Tax ID: 120215784
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No